Weichseldorfer M, Reitz M, Latinovic O
Pharmaceutics. 2021; 13(11).
PMID: 34834213
PMC: 8621549.
DOI: 10.3390/pharmaceutics13111798.
Weichseldorfer M, Affram Y, Heredia A, Rikhtegaran-Tehrani Z, Sajadi M, Williams S
J Transl Med. 2021; 19(1):453.
PMID: 34717655
PMC: 8557591.
DOI: 10.1186/s12967-021-03120-w.
Payne H, Chan M, Watters S, Otwombe K, Hsiao N, Babiker A
AIDS Res Ther. 2021; 18(1):63.
PMID: 34587974
PMC: 8482761.
DOI: 10.1186/s12981-021-00389-1.
Scholz E, Mwangi J, De la Cruz G, Nekorchuk M, Chan C, Busman-Sahay K
Antimicrob Agents Chemother. 2021; 65(6).
PMID: 33782003
PMC: 8315948.
DOI: 10.1128/AAC.00019-21.
Scholz E, Kashuba A
Clin Pharmacol Ther. 2021; 109(4):918-927.
PMID: 33529355
PMC: 8005487.
DOI: 10.1002/cpt.2186.
Antiretroviral Drug Concentrations in Lymph Nodes: A Cross-Species Comparison of the Effect of Drug Transporter Expression, Viral Infection, and Sex in Humanized Mice, Nonhuman Primates, and Humans.
Burgunder E, Fallon J, White N, Schauer A, Sykes C, Remling-Mulder L
J Pharmacol Exp Ther. 2019; 370(3):360-368.
PMID: 31235531
PMC: 6695867.
DOI: 10.1124/jpet.119.259150.
Specific Activation of HIV-1 by a Bromodomain Inhibitor from Monocytic Cells in Humanized Mice under Antiretroviral Therapy.
Li G, Zhang Z, Reszka-Blanco N, Li F, Chi L, Ma J
J Virol. 2019; 93(12).
PMID: 30971469
PMC: 6613761.
DOI: 10.1128/JVI.00233-19.
HIV-1 latency: an update of molecular mechanisms and therapeutic strategies.
Battistini A, Sgarbanti M
Viruses. 2014; 6(4):1715-58.
PMID: 24736215
PMC: 4014718.
DOI: 10.3390/v6041715.
Successful isolation of infectious and high titer human monocyte-derived HIV-1 from two subjects with discontinued therapy.
Wang T, Xu Y, Zhu H, Andrus T, Ivanov S, Pan C
PLoS One. 2013; 8(5):e65071.
PMID: 23741458
PMC: 3669022.
DOI: 10.1371/journal.pone.0065071.
Cell-associated HIV RNA: a dynamic biomarker of viral persistence.
Pasternak A, Lukashov V, Berkhout B
Retrovirology. 2013; 10:41.
PMID: 23587031
PMC: 3637491.
DOI: 10.1186/1742-4690-10-41.
Overcoming pharmacologic sanctuaries.
Cory T, Schacker T, Stevenson M, Fletcher C
Curr Opin HIV AIDS. 2013; 8(3):190-5.
PMID: 23454865
PMC: 3677586.
DOI: 10.1097/COH.0b013e32835fc68a.
Conserved hydrogen bonds and water molecules in MDR HIV-1 protease substrate complexes.
Liu Z, Wang Y, Yedidi R, Dewdney T, Reiter S, Brunzelle J
Biochem Biophys Res Commun. 2012; 430(3):1022-7.
PMID: 23261453
PMC: 4520401.
DOI: 10.1016/j.bbrc.2012.12.045.
Short communication: HIV type 1 accumulates in influenza-specific T cells in subjects receiving seasonal vaccination in the context of effective antiretroviral therapy.
Jones R, Kovacs C, Chun T, Ostrowski M
AIDS Res Hum Retroviruses. 2012; 28(12):1687-92.
PMID: 22734882
PMC: 3505056.
DOI: 10.1089/AID.2012.0115.
Nine crystal structures determine the substrate envelope of the MDR HIV-1 protease.
Liu Z, Wang Y, Brunzelle J, Kovari I, Kovari L
Protein J. 2011; 30(3):173-83.
PMID: 21394574
DOI: 10.1007/s10930-011-9316-2.
Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART.
Ensoli B, Bellino S, Tripiciano A, Longo O, Francavilla V, Marcotullio S
PLoS One. 2010; 5(11):e13540.
PMID: 21085635
PMC: 2978690.
DOI: 10.1371/journal.pone.0013540.
Characterization of HIV-1 RNA forms in the plasma of patients undergoing successful HAART.
Lopez C, Vazquez M, Hill M, Colon M, Porrata-Doria T, Johnston I
Arch Virol. 2010; 155(6):895-903.
PMID: 20414690
PMC: 2880236.
DOI: 10.1007/s00705-010-0659-3.
Identification of a potential pharmacological sanctuary for HIV type 1 in a fraction of CD4(+) primary cells.
Valentin A, Morrow M, Poirier R, Aleman K, Little R, Yarchoan R
AIDS Res Hum Retroviruses. 2010; 26(1):79-88.
PMID: 20059395
PMC: 2858927.
DOI: 10.1089/aid.2009.0044.
Combination antiretroviral drugs in PLGA nanoparticle for HIV-1.
Destache C, Belgum T, Christensen K, Shibata A, Sharma A, Dash A
BMC Infect Dis. 2009; 9:198.
PMID: 20003214
PMC: 2807870.
DOI: 10.1186/1471-2334-9-198.
HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy.
Mavigner M, Delobel P, Cazabat M, Dubois M, LFaqihi-Olive F, Raymond S
PLoS One. 2009; 4(10):e7658.
PMID: 19876401
PMC: 2765414.
DOI: 10.1371/journal.pone.0007658.
A simian immunodeficiency virus-infected macaque model to study viral reservoirs that persist during highly active antiretroviral therapy.
Dinoso J, Rabi S, Blankson J, Gama L, Mankowski J, Siliciano R
J Virol. 2009; 83(18):9247-57.
PMID: 19570871
PMC: 2738256.
DOI: 10.1128/JVI.00840-09.
